Achieving clinically meaningful changes in haemoglobin levels in patients with non‐transfusion‐dependent β‐thalassaemia treated with luspatercept: A post hoc analysis of the phase 2 BEYOND trial
Year: 2025
Type: article
Abstract: In this post hoc analysis of the phase 2 BEYOND trial, the majority of patients with non-transfusion-dependent β-thalassaemia achieved clinically meaningful haemoglobin levels ≥10.0 g/dL and increases from baseline ≥1.0 g/dL, thresholds associated with reduced risk of morbidity and mortality and recommended as an indication and target for treatment by international management guidelines, respectively.
Source: British Journal of Haematology
DOI: 10.1111/bjh.70227
Institutions: Khalifa University of Science and Technology, Weill Cornell Medicine, American University of Beirut Medical Center, American University of Beirut, University College London, National and Kapodistrian University of Athens, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (Switzerland), Bristol-Myers Squibb (United Kingdom), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
Funders: Bristol-Myers Squibb, Acceleron
OpenAlex ID: W4415567721